Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05882721
Other study ID # Sofwave19
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 20, 2023
Est. completion date November 15, 2023

Study information

Verified date September 2023
Source Sofwave Medical LTD
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Open-label, non-randomized, prospective, multi-center, self-controlled clinical study with masked evaluation.


Description:

Eligible patients will receive 2 treatments (4 ± 2 weeks apart) on either one side (right or left) or both sides of the lateral/posterior upper thigh and/or buttocks using SofWave System with the Form applicator ('2X'). Treatment may be administered after the enrollment and screening at the first visit, or it may occur later following the enrollment and screening activities based on site scheduling availabilities. All patients will return to the clinic for one follow up visit at 3 months ± 1 week post last treatment (FU1). Methodology described in the protocol to evaluate efficacy and safety of treatments will be carried out at each visit at the clinic.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date November 15, 2023
Est. primary completion date November 1, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: 1. Healthy female subjects > 18 years of age and < 60 years of age 2. Not pregnant or lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide) or abstinence. 3. Have visible cellulite in the upper thigh and/or buttock areas. 4. Seeking treatment of cellulite in the upper thigh and/or buttock areas. 5. Stable weight nominally ±5% for at least past 6 months 6. Subject agrees to maintain her weight (i.e., within 5% of total body weight) by not making any major changes in their diet or exercise routine during the study course. 7. Subject did not undergo invasive or energy-based cellulite treatments (liposuction, subcision, RF, laser, ESWT, etc.) for the prior 12 months. 8. Subject did not use topical based cellulite treatments for prior 6 months and will not use during the trial (except for the study related procedures) 9. Subject agrees not to undergo any other cellulite treatments for a period of 3 months following SofWave treatment 10. Willing to have photographs of the treated areas. Agree for de-identified study images to be used in evaluations, publications, and presentations. 11. Able and willing to comply with all visits, treatments and evaluations schedules and requirements. 12. Able to understand and provide written Informed Consent. Exclusion Criteria: 1. Pregnant or planning to become pregnant during the duration of the study, having given birth less than 3 months ago, and/or breast feeding 2. Currently heavy smoker or has history of heavy smoking (25 cigarettes per day or more) in past 10 years 3. BMI>=30kg/m2 4. Non-stable weight nominally ±5% for at least past 6 months 5. Currently taking or has taken diet pills or weight control supplements within the past month 6. History of severe migraine tendency 7. History of Epileptic seizures 8. History of chronic drug or alcohol abuse 9. History of coagulopathy(ies) and/or on anticoagulant medication 10. History of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising 11. Medical disorder that would hinder the wound healing or immune response (such as blood disorder, inflammatory disease, etc.) 12. Active implanted device such as a pacemaker, defibrillator, cochlear implants, nerve/brain stimulators or drug delivery system 13. Known allergy to lidocaine or epinephrine or antibiotics 14. Active malignancy or history of malignancy in the past 5 years 15. Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), lupus, porphyria, or pertinent neurological disorders (i.e., any disease state that in the opinion of the investigator may interfere with the anesthesia, treatment, or healing process) 16. History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications 17. Suffering from hormonal imbalance, whether related to thyroid, pituitary, or androgen 18. History of significant lymphatic drainage problems 19. History of epidermal or dermal disorders (particularly involving collagen or microvascularity), including collagen vascular disease or vasculitic disorders. 20. Skin disorders (skin infections or rashes, extensive scarring, psoriasis, etc.) in the treatment area. 21. Severe solar elastosis on the intended to treat area. 22. Significant scarring, atrophic scars in the area to be treated, or has a history of atrophic scars or keloids or prone to bruising 23. Tattoo or former tattoo at or near treatment area 24. Presence of an implant (metal or plastic) in or adjacent to area of intended treatment (vascular stent, or implants in the hips, knees, etc) 25. Inability to understand the protocol or to give informed consent 26. On-going use of psychiatric medication 27. Unable or unwilling to comply with the study requirements and procedures 28. Unwilling to have research photos taken of treatment areas 29. Currently enrolled in a clinical study of any other unapproved investigational drug or device 30. Any other condition that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Sofwave
The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues. Other Names: SUPERB

Locations

Country Name City State
United States Main Line Center for Laser Surgery Ardmore Pennsylvania
United States Schweiger Dermatology GP Research Hackensack New Jersey
United States Tennessee Clinical Research Center Nashville Tennessee
United States UnionDerm New York New York
United States Laser & Skin Surgery Center of Northern California Sacramento California

Sponsors (1)

Lead Sponsor Collaborator
Sofwave Medical LTD

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Outcome Measure: Rate of improvement in the appearance of cellulite on the upper thigh/buttock area following Sofwave treatments based on 6 points simplified Cellulite Severity Scale (CSS), as evaluated by independent masked reviewers. 3 months post treatment follow-up visit
See also
  Status Clinical Trial Phase
Completed NCT03550157 - Structural Changes of Subcutaneous Tissue by Ultrasonographies in Patients After Treatment With PnKCelulitis® Program
Completed NCT03078647 - Profound Dermal and SubQ Cartridges for the Treatment of Cellulite N/A
Suspended NCT05441917 - Phototherapy and Radiofrecuency for Cellulite N/A
Completed NCT02942160 - EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite) Phase 2
Active, not recruiting NCT02489994 - Performance of the ePrime System for Cellulite N/A
Completed NCT01209767 - Cryolipolysis and Subcision for Treatment of Cellulite N/A
Completed NCT01702259 - Study of the Effect of Low Level Laser Light Therapy on Reducing the Appearance of Cellulite in the Thighs and Buttocks. N/A
Completed NCT04580303 - CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection Techniques Phase 2
Completed NCT05358847 - Treatment for Cellulite Appearance N/A
Terminated NCT04209530 - Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult Women Phase 2
Completed NCT05064761 - Safety and Effectiveness of Poly-l-lactic Acid (PLLA) for the Improvement in Appearance of Cellulite N/A
Completed NCT03329989 - Safety and Effectiveness of EN3835 in the Treatment of EFP in Women Phase 2
Completed NCT04170296 - Real World CCH Study in Adult Females With Cellulite Phase 3
Completed NCT04419454 - Retrospective Evaluation of Cellulite of Laxity Treatment Using Body Tite
Completed NCT05199506 - Study to Evaluate the Safety and Effectiveness of the RAP Device for the Improvement in the Appearance of Cellulite N/A
Completed NCT05836779 - A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2) Phase 2
Completed NCT05026216 - To Assess the Effectiveness of Multiple Dose, Multiple Concentrations of Qwo, for the Treatment of Mild to Moderate Cellulite. Phase 4
Completed NCT00399854 - Evaluation of the Efficacy of Endermologie in Treatment of Cellulite and Body Contouring Phase 4
Completed NCT00947414 - Cellulite and Extracorporeal Shock Wave N/A
Completed NCT05419505 - Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks Phase 2